|
Inibikase Therapeutics, Inc. (IKT) Avaliação DCF |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Inhibikase Therapeutics, Inc. (IKT) Bundle
Economize tempo e melhore a precisão com a nossa calculadora DCF (IKT)! Utilizando dados reais da Inibikase Therapeutics, Inc. e suposições personalizáveis, essa ferramenta permite que você preveja, analise e valorse (IKT) como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .7 | 3.1 | .1 | .3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 343.92 | -96.02 | 111.03 | -100 | 0.99529 | 0.99529 | 0.99529 | 0.99529 | 0.99529 |
| EBITDA | -2.8 | -14.8 | -18.1 | -19.9 | -28.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -403.52 | -476.23 | -14680.72 | -7643.91 | 100 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 2.8 | 14.8 | .0 | .2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 403.52 | 476.23 | 5.45 | 68.1 | 100 | 74.71 | 74.71 | 74.71 | 74.71 | 74.71 |
| EBIT | -5.6 | -29.5 | -18.1 | -20.1 | -28.6 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -807.05 | -952.47 | -14686.17 | -7712.01 | 100 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 14.0 | 40.8 | 23.1 | 13.3 | 97.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 3.55 | 32.31 | 0 | 100 | 27.17 | 27.17 | 27.17 | 27.17 | 27.17 |
| Inventories | .0 | .1 | 1.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 3.45 | 905.39 | 0 | 100 | 40.69 | 40.69 | 40.69 | 40.69 | 40.69 |
| Accounts Payable | 1.7 | 1.1 | 1.2 | .6 | .9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 246.35 | 35.15 | 932.58 | 248.28 | 100 | 87.03 | 87.03 | 87.03 | 87.03 | 87.03 |
| Capital Expenditure | .0 | .0 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 0 | -197.06 | -5.47 | 100 | -21.09 | -21.09 | -21.09 | -21.09 | -21.09 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -5.7 | -29.6 | -18.0 | -20.1 | -28.6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1.2 | -15.7 | -19.1 | -19.3 | -28.3 | -.9 | .0 | .0 | .0 | .0 |
| WACC, % | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -56 | |||||||||
| Equity Value | 56 | |||||||||
| Diluted Shares Outstanding, MM | 24 | |||||||||
| Equity Value Per Share | 2.34 |
What You Will Get
- Real IKT Financial Data: Pre-filled with Inhibikase Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See IKT's intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Inhibikase Therapeutics, Inc. (IKT).
- Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to fit your analysis.
- Real-time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow evaluations.
- User-Friendly Dashboard: Intuitive charts and summaries to help you visualize your valuation findings.
- Designed for All Skill Levels: An accessible and straightforward layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the prebuilt Excel template with Inhibikase Therapeutics, Inc. (IKT) data included.
- Step 2: Explore the pre-filled sheets to familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Inhibikase Therapeutics, Inc. (IKT) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for Inhibikase Therapeutics, Inc. (IKT)?
- User-Friendly Interface: Crafted for both novice and experienced users.
- Customizable Parameters: Adjust inputs effortlessly to tailor your analysis.
- Real-Time Updates: Observe immediate changes to Inhibikase's valuation as you modify inputs.
- Preloaded Data: Comes equipped with Inhibikase's latest financial figures for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess Inhibikase Therapeutics, Inc.'s (IKT) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Inhibikase Therapeutics, Inc. (IKT).
- Consultants: Efficiently modify the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation techniques in the biotechnology industry.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Inhibikase Therapeutics, Inc. (IKT).
- Real-World Data: Inhibikase’s historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for assessing profitability, efficiency, and leverage specific to Inhibikase Therapeutics, Inc. (IKT).
- Dashboard with Visual Outputs: Visual representations including charts and tables for clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.